{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:22:51Z","timestamp":1793276571368,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT of Korean government","award":["2020M3A9I2108860"],"award-info":[{"award-number":["2020M3A9I2108860"]}]},{"name":"the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT of Korean government","award":["2022M3A9J21081348"],"award-info":[{"award-number":["2022M3A9J21081348"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00204-023-03549-6","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T17:02:02Z","timestamp":1690304522000},"page":"2429-2440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models"],"prefix":"10.1007","volume":"97","author":[{"given":"Sang-Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Seong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Hyun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung\u2010Wook","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Jung","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhee","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-2678","authenticated-orcid":false,"given":"Yong-Bum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"3549_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2020.04.022","volume":"27","author":"DR Burton","year":"2020","unstructured":"Burton DR, Walker LM (2020) Rational vaccine design in the time of COVID-19. Cell Host Microbe 27:695\u2013698. https:\/\/doi.org\/10.1016\/j.chom.2020.04.022","journal-title":"Cell Host Microbe"},{"key":"3549_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12026-020-09154-4","volume":"68","author":"D Calina","year":"2020","unstructured":"Calina D, Sarkar C, Arsene AL et al (2020) Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol Res 68:315\u2013324. https:\/\/doi.org\/10.1007\/s12026-020-09154-4","journal-title":"Immunol Res"},{"key":"3549_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.vascn.2004.03.009","volume":"50","author":"AY Chiang","year":"2004","unstructured":"Chiang AY, Smith WC, Main BW, Sarazan RD (2004) Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs. J Pharmacol Toxicol Methods 50:121\u2013130. https:\/\/doi.org\/10.1016\/j.vascn.2004.03.009","journal-title":"J Pharmacol Toxicol Methods"},{"key":"3549_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer D, Juno JA, Khoury D et al (2021) Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol 21:395\u2013404. https:\/\/doi.org\/10.1038\/s41577-021-00550-x","journal-title":"Nat Rev Immunol"},{"key":"3549_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai L, Zheng T, Xu K et al (2020) A universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182:722-733.e11. https:\/\/doi.org\/10.1016\/j.cell.2020.06.035","journal-title":"Cell"},{"key":"3549_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00204-021-03221-x","volume":"96","author":"X Dai","year":"2022","unstructured":"Dai X, Zhao W, Tong X et al (2022) Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque. Arch Toxicol 96:1437\u20131453. https:\/\/doi.org\/10.1007\/s00204-021-03221-x","journal-title":"Arch Toxicol"},{"key":"3549_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/children8070607","volume":"8","author":"BB Das","year":"2021","unstructured":"Das BB, Moskowitz WB, Taylor MB, Palmer A (2021) Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far? Children (Basel) 8:607. https:\/\/doi.org\/10.3390\/children8070607","journal-title":"Children (Basel)"},{"key":"3549_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.vaccine.2010.11.011","volume":"29","author":"KE Dolter","year":"2011","unstructured":"Dolter KE, Evans CF, Ellefsen B et al (2011) Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine 29:795\u2013803. https:\/\/doi.org\/10.1016\/j.vaccine.2010.11.011","journal-title":"Vaccine"},{"key":"3549_CR9","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","volume":"25","author":"L Du","year":"2007","unstructured":"Du L, Zhao G, He Y et al (2007) Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25:2832\u20132838. https:\/\/doi.org\/10.1016\/j.vaccine.2006.10.031","journal-title":"Vaccine"},{"key":"3549_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41581-022-00571-2","volume":"18","author":"E Dub\u00e9","year":"2022","unstructured":"Dub\u00e9 E, MacDonald NE (2022) COVID-19 vaccine hesitancy. Nat Rev Nephrol 18:409\u2013410. https:\/\/doi.org\/10.1038\/s41581-022-00571-2","journal-title":"Nat Rev Nephrol"},{"key":"3549_CR11","unstructured":"European Medicines Agency (2019) Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. (EMA\/CAT\/852602\/20185). https:\/\/www.ema.europa.eu\/en\/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal"},{"key":"3549_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxrep.2020.12.001","volume":"8","author":"K Farsalinos","year":"2021","unstructured":"Farsalinos K, Poulas K, Kouretas D et al (2021) Improved strategies to counter the COVID-19 pandemic: lockdowns vs. primary and community healthcare. Toxicol Rep 8:1\u20139. https:\/\/doi.org\/10.1016\/j.toxrep.2020.12.001","journal-title":"Toxicol Rep"},{"key":"3549_CR13","first-page":"36791","volume":"66","author":"FDA, US","year":"2001","unstructured":"FDA, US (2001) ICHS7A: safety pharmacology studies for human pharmaceuticals. Fed Regist 66:36791\u201336792","journal-title":"Fed Regist"},{"key":"3549_CR14","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1016\/j.vaccine.2022.07.007","volume":"40","author":"K Goddard","year":"2022","unstructured":"Goddard K, Lewis N, Fireman B et al (2022) Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine 40:5153\u20135159. https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.007","journal-title":"Vaccine"},{"key":"3549_CR15","doi-asserted-by":"publisher","unstructured":"Green MD, Hussain Al-Humadi N (2013) Preclinical toxicology of vaccines. In: A comprehensive guide to toxicology in preclinical drug development. pp 709\u2013735. https:\/\/doi.org\/10.1016\/B978-0-12-387815-1.00025-3","DOI":"10.1016\/B978-0-12-387815-1.00025-3"},{"key":"3549_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo YR, Cao QD, Hong ZS et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2014an update on the status. Mil Med Res 7:11. https:\/\/doi.org\/10.1186\/s40779-020-00240-0","journal-title":"Mil Med Res"},{"key":"3549_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","volume":"324","author":"Y He","year":"2004","unstructured":"He Y, Zhou Y, Liu S et al (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324:773\u2013781. https:\/\/doi.org\/10.1016\/j.bbrc.2004.09.106","journal-title":"Biochem Biophys Res Commun"},{"key":"3549_CR18","doi-asserted-by":"publisher","first-page":"927306","DOI":"10.3389\/fmicb.2022.927306","volume":"13","author":"M Heidary","year":"2022","unstructured":"Heidary M, Kaviar VH, Shirani M et al (2022) A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol 13:927306. https:\/\/doi.org\/10.3389\/fmicb.2022.927306","journal-title":"Front Microbiol"},{"key":"3549_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","volume":"8","author":"AF Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez AF, Calina D, Poulas K, Docea AO, Tsatsakis AM (2021) Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep 8:871\u2013879. https:\/\/doi.org\/10.1016\/j.toxrep.2021.04.003","journal-title":"Toxicol Rep"},{"key":"3549_CR20","doi-asserted-by":"publisher","first-page":"e0008548","DOI":"10.1371\/journal.pntd.0008548","volume":"14","author":"PJ Hotez","year":"2020","unstructured":"Hotez PJ, Bottazzi ME (2020) Developing a low-cost and accessible COVID-19 vaccine for global health. PLoS Negl Trop Dis 14:e0008548. https:\/\/doi.org\/10.1371\/journal.pntd.0008548","journal-title":"PLoS Negl Trop Dis"},{"key":"3549_CR21","first-page":"36791","volume":"66","author":"ICH guidline","year":"2001","unstructured":"ICH guidline (2001) Safety pharmacology studies for human pharmaceuticals S7A. Fed Regist 66:36791\u201336792","journal-title":"Fed Regist"},{"key":"3549_CR22","unstructured":"ICH guideline (2005) The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt Interval Prolongation) by human pharmaceuticals, S7B. http:\/\/www.ich.org\/products\/guidelines\/safety\/article\/safety-guidelines.html. Accessed March 2014"},{"key":"3549_CR23","unstructured":"ICH guideline (2009) Non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals, M3 (R2). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf. Accessed 11 Dec 2020"},{"key":"3549_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/BF00401402","volume":"13","author":"S Irwin","year":"1968","unstructured":"Irwin S (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13:222\u2013257. https:\/\/doi.org\/10.1007\/BF00401402","journal-title":"Psychopharmacologia"},{"key":"3549_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.yrtph.2016.09.022","volume":"81","author":"JW Jeong","year":"2016","unstructured":"Jeong JW, Yu C, Lee JH et al (2016) Subacute toxicity evaluation of KR-33493, FAF1 inhibitor for a new anti-Parkinson\u2019s disease agent, after oral administration in rats and dogs. Regul Toxicol Pharmacol 81:387\u2013396. https:\/\/doi.org\/10.1016\/j.yrtph.2016.09.022","journal-title":"Regul Toxicol Pharmacol"},{"key":"3549_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1586\/erv.12.126","volume":"11","author":"S Jiang","year":"2012","unstructured":"Jiang S, Bottazzi ME, Du L et al (2012) Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 11:1405\u20131413. https:\/\/doi.org\/10.1586\/erv.12.126","journal-title":"Expert Rev Vaccines"},{"key":"3549_CR27","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/AAC.02232-13","volume":"58","author":"SY Jun","year":"2014","unstructured":"Jun SY, Jung GM, Yoon SJ et al (2014) Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 58:2084\u20132088. https:\/\/doi.org\/10.1128\/AAC.02232-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3549_CR28","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","volume":"34","author":"S Kashte","year":"2021","unstructured":"Kashte S, Gulbake A, El-Amin Iii SF, Gupta A (2021) COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell 34:711\u2013733. https:\/\/doi.org\/10.1007\/s13577-021-00512-4","journal-title":"Hum Cell"},{"key":"3549_CR29","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1080\/22221751.2021.1971569","volume":"10","author":"LI Kozlovskaya","year":"2021","unstructured":"Kozlovskaya LI, Piniaeva AN, Ignatyev GM et al (2021) Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect 10:1790\u20131806. https:\/\/doi.org\/10.1080\/22221751.2021.1971569","journal-title":"Emerg Microbes Infect"},{"key":"3549_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09638237.2020.1757052","volume":"30","author":"A Kumar","year":"2021","unstructured":"Kumar A, Nayar KR (2021) COVID 19 and its mental health consequences. J Ment Health 30:1\u20132. https:\/\/doi.org\/10.1080\/09638237.2020.1757052","journal-title":"J Ment Health"},{"key":"3549_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.yrtph.2015.05.007","volume":"72","author":"J Lee","year":"2015","unstructured":"Lee J, Song J, Jeong EJ et al (2015) Developmental toxicity assessment of the new turf herbicide, methiozolin ([5-(2,6-difluorobenzyl)oxymethyl-5-methyl-3,3(3-methylthiophen-2-yl)-1,2-isoxazoline]), in rabbits. Regul Toxicol Pharmacol 72:639\u2013645. https:\/\/doi.org\/10.1016\/j.yrtph.2015.05.007","journal-title":"Regul Toxicol Pharmacol"},{"key":"3549_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Z Liu","year":"2020","unstructured":"Liu Z, Xu W, Xia S et al (2020) RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther 5:282. https:\/\/doi.org\/10.1038\/s41392-020-00402-5","journal-title":"Signal Transduct Target Ther"},{"key":"3549_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41591-021-01459-7","volume":"27","author":"S Machingaidze","year":"2021","unstructured":"Machingaidze S, Wiysonge CS (2021) Understanding COVID-19 vaccine hesitancy. Nat Med 27:1338\u20131339. https:\/\/doi.org\/10.1038\/s41591-021-01459-7","journal-title":"Nat Med"},{"key":"3549_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMp2000929","volume":"382","author":"VJ Munster","year":"2020","unstructured":"Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E (2020) A novel coronavirus emerging in China\u2014key questions for impact assessment. N Engl J Med 382:692\u2013694. https:\/\/doi.org\/10.1056\/NEJMp2000929","journal-title":"N Engl J Med"},{"key":"3549_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola M, Alsafi Z, Sohrabi C et al (2020) The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg 78:185\u2013193. https:\/\/doi.org\/10.1016\/j.ijsu.2020.04.018","journal-title":"Int J Surg"},{"key":"3549_CR36","doi-asserted-by":"publisher","unstructured":"Organisation for Economic Co-operation and Development (OECD) (2002) Acute Dermal Irritation\/Corrosion. OECD Guideline for the testing of chemicals, 404, 13. https:\/\/doi.org\/10.1787\/9789264070622-en","DOI":"10.1787\/9789264070622-en"},{"key":"3549_CR37","doi-asserted-by":"publisher","first-page":"153161","DOI":"10.1016\/j.tox.2022.153161","volume":"471","author":"R Oliva-Hern\u00e1ndez","year":"2022","unstructured":"Oliva-Hern\u00e1ndez R, Fari\u00f1as-Medina M, Hern\u00e1ndez-Salazar T et al (2022) Repeat-dose and local tolerance toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats. Toxicology 471:153161. https:\/\/doi.org\/10.1016\/j.tox.2022.153161","journal-title":"Toxicology"},{"key":"3549_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yrtph.2017.11.007","volume":"92","author":"SJ Park","year":"2018","unstructured":"Park SJ, Noh J, Jeong EJ et al (2018) Subchronic oral toxicity study of Korean red ginseng extract in Sprague-Dawley rats with a 4-week recovery period. Regul Toxicol Pharmacol 92:83\u201393. https:\/\/doi.org\/10.1016\/j.yrtph.2017.11.007","journal-title":"Regul Toxicol Pharmacol"},{"key":"3549_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/01926233221090518","volume":"50","author":"Y Ramot","year":"2022","unstructured":"Ramot Y, Kronfeld N, Ophir Y et al (2022) Toxicity and local tolerance of a novel spike protein RBD vaccine against SARS-CoV-2, produced using the C1 Thermothelomyces heterothallica protein expression platform. Toxicol Pathol 50:294\u2013307. https:\/\/doi.org\/10.1177\/01926233221090518","journal-title":"Toxicol Pathol"},{"issue":"Suppl 2","key":"3549_CR40","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1111\/odi.13916","volume":"28","author":"LP Samaranayake","year":"2022","unstructured":"Samaranayake LP, Seneviratne CJ, Fakhruddin KS (2022) Coronavirus disease 2019 (COVID-19) vaccines: a concise review. Oral Dis 28(Suppl 2):2326\u20132336. https:\/\/doi.org\/10.1111\/odi.13916","journal-title":"Oral Dis"},{"key":"3549_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/15376519309044576","volume":"3","author":"RD Sarazan","year":"1993","unstructured":"Sarazan RD (1993) Chronically instrumented conscious dog model in cardiovascular toxicology studies. Toxicol Methods 3:195\u2013211. https:\/\/doi.org\/10.3109\/15376519309044576","journal-title":"Toxicol Methods"},{"key":"3549_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0192623319875085","volume":"48","author":"RS Sellers","year":"2020","unstructured":"Sellers RS, Nelson K, Bennet B et al (2020) Scientific and regulatory policy committee points to consider*: approaches to the conduct and interpretation of vaccine safety studies for clinical and anatomic pathologists. Toxicol Pathol 48:257\u2013276. https:\/\/doi.org\/10.1177\/0192623319875085","journal-title":"Toxicol Pathol"},{"key":"3549_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12932\/AP-200220-0773","volume":"38","author":"B Shanmugaraj","year":"2020","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W (2020) Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 38:10\u201318. https:\/\/doi.org\/10.12932\/AP-200220-0773","journal-title":"Asian Pac J Allergy Immunol"},{"key":"3549_CR44","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1016\/j.vaccine.2022.05.087","volume":"40","author":"B Shanmugaraj","year":"2022","unstructured":"Shanmugaraj B, Khorattanakulchai N, Panapitakkul C et al (2022) Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: protective efficacy, immunogenicity, safety, and toxicity. Vaccine 40:4440\u20134452. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.087","journal-title":"Vaccine"},{"key":"3549_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/vaccines9030300","volume":"9","author":"P Soares","year":"2021","unstructured":"Soares P, Rocha JV, Moniz M et al (2021) Factors associated with COVID-19 vaccine hesitancy. Vaccines (Basel) 9:300. https:\/\/doi.org\/10.3390\/vaccines9030300","journal-title":"Vaccines (Basel)"},{"key":"3549_CR46","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","volume":"39","author":"M Soy","year":"2020","unstructured":"Soy M, Keser G, Atag\u00fcnd\u00fcz P, Tabak F, Atag\u00fcnd\u00fcz I, Kayhan S (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39:2085\u20132094. https:\/\/doi.org\/10.1007\/s10067-020-05190-5","journal-title":"Clin Rheumatol"},{"key":"3549_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"W Tai","year":"2021","unstructured":"Tai W, He L, Zhang X et al (2021) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 17:613\u2013620. https:\/\/doi.org\/10.1038\/s41423-020-0400-4","journal-title":"Cell Mol Immunol"},{"key":"3549_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","volume":"194","author":"G Troiano","year":"2021","unstructured":"Troiano G, Nardi A (2021) Vaccine hesitancy in the era of COVID-19. Public Health 194:245\u2013251. https:\/\/doi.org\/10.1016\/j.puhe.2021.02.025","journal-title":"Public Health"},{"key":"3549_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.14740\/jocmr4490","volume":"13","author":"D Vasireddy","year":"2021","unstructured":"Vasireddy D, Atluri P, Malayala SV, Vanaparthy R, Mohan G (2021) Review of COVID-19 vaccines approved in the United States of America for emergency use. J Clin Med Res 13:204\u2013213. https:\/\/doi.org\/10.14740\/jocmr4490","journal-title":"J Clin Med Res"},{"key":"3549_CR50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/vaccines9070747","volume":"9","author":"R Wagner","year":"2021","unstructured":"Wagner R, Hildt E, Grabski E et al (2021) Accelerated development of COVID-19 vaccines: technology platforms, benefits, and associated risks. Vaccines (basel) 9:747. https:\/\/doi.org\/10.3390\/vaccines9070747","journal-title":"Vaccines (basel)"},{"key":"3549_CR51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","volume":"11","author":"N Wang","year":"2020","unstructured":"Wang N, Shang J, Jiang S, Du L (2020) Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol 11:298. https:\/\/doi.org\/10.3389\/fmicb.2020.00298","journal-title":"Front Microbiol"},{"key":"3549_CR52","doi-asserted-by":"publisher","first-page":"e2218512","DOI":"10.1001\/jamanetworkopen.2022.18512","volume":"5","author":"ES Weintraub","year":"2022","unstructured":"Weintraub ES, Oster ME, Klein NP (2022) Myocarditis or pericarditis following mRNA COVID-19 vaccination. JAMA Netw Open 5:e2218512. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.18512","journal-title":"JAMA Netw Open"},{"key":"3549_CR53","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang J, Wang W, Chen Z et al (2020) A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586:572\u2013577. https:\/\/doi.org\/10.1038\/s41586-020-2599-8","journal-title":"Nature"},{"key":"3549_CR54","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3390\/vaccines10122080","volume":"10","author":"H Yang","year":"2022","unstructured":"Yang H, Pan W, Chen G et al (2022) Preclinical toxicity and immunogenicity of a COVID-19 vaccine (ZF2001) in Cynomolgus Monkeys. Vaccines (Basel) 10:2080. https:\/\/doi.org\/10.3390\/vaccines10122080","journal-title":"Vaccines (Basel)"},{"key":"3549_CR55","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/14760584.2014.912134","volume":"13","author":"N Zhang","year":"2014","unstructured":"Zhang N, Jiang S, Du L (2014) Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 13:761\u2013774. https:\/\/doi.org\/10.1586\/14760584.2014.912134","journal-title":"Expert Rev Vaccines"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-023-03549-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03549-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:04:47Z","timestamp":1691215487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-023-03549-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3549"],"URL":"https:\/\/doi.org\/10.1007\/s00204-023-03549-6","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Animal and Plant Quarantine Agency of Korea.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}